Breast Cancer Archives | Page 3 of 6

Oncotarget News

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

August 21, 2023

Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 21, 2023 – A new... read more

Figure 1: Multi-clonal ER expression in DCIS.

Oncotarget

Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)

August 1, 2023

We have discussed in detail the clinical implications of ER in avoiding overtreatment and undertreatment in DCIS.”BUFFALO, NY- August 1, 2023 – A new editorial paper was published in Oncotarget's... read more

Figure 1: An integrated representation of the multifaceted effects of progesterone in breast cancer.

Oncotarget

Deciphering Progesterone’s Mechanisms of Action in Breast Cancer

July 10, 2023

The mechanisms underlying the observed effects of progesterone on breast cancer outcomes are unclear.”BUFFALO, NY- July 10, 2023 – A new research perspective was published in Oncotarget's Volume 14 on... read more

Figure 1: Upon activation by the specific agonist LY500307 ERβ binds to estrogen receptor binding elements (ERE) in regulatory regions of GPR141 and ELMO1 genes and suppresses their transcription, which in turn leads to diminished RhoC activation, reduced actin-based cell migration and metastasis.

Oncotarget

ERβ as a Mediator of Estrogen Signaling in Inflammatory Breast Cancer

July 3, 2023

The mechanism of the anti-metastatic activity of ERβ was investigated [...]”BUFFALO, NY- July 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “... read more

Figure 1: Proposed pathway of ACSL4-mediated stimulation of quadruple negative breast cancer cells

Oncotarget

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

June 14, 2023

ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.”BUFFALO, NY- June... read more

Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression

Oncotarget

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

June 5, 2023

The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”BUFFALO, NY- June 5, 2023 – A new research paper was published... read more

Oncotarget

Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts

May 25, 2023

Dr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular... read more

Figure 7: Schematic demonstrating the role of GPR141 in mediating breast cancer development and progression.

Oncotarget

GPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and The p-mTOR/p53 Axis

May 22, 2023

This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.”BUFFALO, NY- May 22, 2023 – A new research paper... read more

Oncotarget

Behind the Study: Role of Biomarkers in Management of Lumps in the Breast

May 10, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, describes a recent research perspective he authored that was published by Oncotarget in Volume 14, entitled, “Crossroads: the... read more

Oncotarget

Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast

May 2, 2023

A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system.”BUFFALO, NY- May 2, 2023 –... read more